重组人内皮抑制素(五天泵)和白蛋白紫杉醇和奈达铂一线治疗晚期(ⅢB-Ⅳ期)非小细胞肺鳞癌的临床研究

Clinical Study of Recombinant Human Endostatin(5-Day Pump)and Albumin Paclitaxel and Nedaplatin in First-Line Treatment of Advanced Stage(StageⅢB-Ⅳ)Non-Small Cell Lung Squamous Cell Carcinoma

目的 探讨重组人内皮抑制素静脉输注泵入5 d联合白蛋白紫杉醇、奈达铂一线治疗晚期肺鳞癌患者的近期疗效和安全性。方法 纳入泉州市安溪县医院2021年7月至2022年7月诊治的晚期(ⅢB-IV期)肺鳞癌患者。采用重组人内皮抑制素15 mg/(m~2·d),持续24 h静脉输注泵入,连续5 d,联合白蛋白紫杉醇、奈达铂两种化疗药物方案治疗,21 d为1周期,根据实际情况行4~6周期治疗。评估近期疗效和安全性。结果 共入组30例患者,中位年龄61.5岁,男性24例(80.0%)。30例均完成2周期治疗,客观有效率43.3%,疾病控制率93.3%。20例完成4周期治疗,客观有效率55.0%,疾病控制率95.0%。6例完成6周期治疗,客观有效率33.3%,疾病控制率83.3%。治疗过程中与重组人内皮抑制素相关的主要不良反应有1~2级心脏毒性及高血压,未发生3级以上药物不良反应。结论 重组人内皮抑制素持续输注泵入5 d联合白蛋白紫杉醇和奈达铂一线治疗晚期肺鳞癌,进行2周期或4周期治疗后有效率和疾病控制率均有明显改善,患者身体耐受性好,不良反应少。

Objective To explore the recent efficacy and safety of recombinant human endostatin injection pumped by intravenous infusion for 5 d combined with albumin paclitaxel and nedaplatin in the first-line treatment of patients with advanced lung squamous carcinoma.Methods Patients with advanced(stageⅢB-Ⅳ)squamous lung cancer diagnosed and treated from July 2021 to July 2022 in Anxi County Hospital of Quanzhou City were included.recombinant human endostatin injection 15 mg/(m2•d),continuous 24 h intravenous infusion pumping,for 5 d,combined with albumin paclitaxel,nedaplatin two chemotherapeutic drug regimens for treatment,21 d for 1 cycle,according to the actual situation of the line of 4 to 6 cycles of treatment.Evaluate the recent efficacy and safety.Results A total of 30 patients were enrolled,with a median age of 61.5 years,24(80.0%)were male.30 patients completed 2 cycles of treatment,with an objective effectiveness rate of 43.3%and a disease control rate of 93.3%.20 patients completed 4 cycles of treatment,with an objective effectiveness rate of 55.0%and a disease control rate of 95.0%.6 cases completed 6 cycles of treatment,with an objective effectiveness rate of 33.3%and a disease control rate of 83.3%.83.3%.The main toxic side effects associated with recombinant human endostatin injection during treatment were grade 1-2 cardiotoxicity and hypertension,and no grade 3 or above adverse drug reactions occurred.Conclusions Recombinant human endostatin injection continuous infusion pumped for 5 d combined with albumin paclitaxel and nedaplatin for the first-line treatment of advanced lung squamous carcinoma showed significant improvement in the effective rate and disease control rate after 2 cycles or 4 cycles of treatment,and was well tolerated by the patients with fewer adverse reactions.